Cell Impact was listed on the Nasdaq First North Growth Market in 2013 and has grown substantially over the years. With a market capitalization of SEK 2.5 billion and upwards of 30,000 shareholders, it was time to refresh our investor pages.
As our investor community grows beyond Sweden, we felt the need to add English as a second language for those who don't speak Swedish. That's why most of our press releases (from 2019) and financial reports (from 2020) are also available in English.
Our goal remains - to serve the community with up-to-date, accurate information to simplify investment decisions. We hope that you will find our new IR site easy to navigate and a pleasure to use!
Pär Teike, CEO
Stefan Axellie, CFO
Karlskoga, Sweden
As with any new website, we are humble enough to acknowledge that we might have missed something. So if you find a bug or have a suggestion for something we haven't thought of, please feel free to let us know!
Just send an email to bugreport@cellimpact.com, and we'll have a look. Thank you!
Cell Impact AB (Nasdaq First North Growth Market: CI B) ("Cell Impact" or the "Company") today announces an updated indicative timetable for the fully guaranteed Rights Issue. The updated indicative timetable deviates from the previously communicated indicative timetable due to a postponed prospectus approval as a result of high workload for the Swedish Financial Supervisory Authority's prospectus unit.
An extraordinary general meeting of Cell Impact AB (publ) was held on 16 November 2021 whereby the shareholders, inter alia, authorized the board of directors to resolve upon issue of shares, warrants and/or convertibles.
The shareholders of Cell Impact AB (publ), reg. no. 556576-6655, are hereby invited to participate in an extraordinary general meeting on Tuesday 16 November 2021.
Subscribe to automatically receive our press releases in your mailbox.
